QuantusAI Global

AI platform to generate, adapt, and consolidate value evidence—craft value messages, train teams, and measure impact.

[QuantusAI Global @QuantusGlobal_]

In England, 57.5% of drugs got a "no" in NICE's first round. 72.6% of those ended in a "yes", mostly through a discount or a narrower population.

The first "no" opens the price talks. Study in the reply.

#MarketAccess #HEOR #HTA #NICE #DrugPricing

[QuantusAI Global @QuantusGlobal_]

Will AI be accepted in a dossier?

NICE, EMA and FDA have already published their positions.

But they don't decide in Colombia, Mexico or Brazil.

International references ≠ rules for LATAM.

🔗 Link in bio

#HTA #MarketAccess #QuantusAI

[QuantusAI Global @QuantusGlobal_]

Mirzayeh Fashami et al., PharmacoEconomics-Open 2024: https://t.co/0xMtSMO3Aq

[QuantusAI Global @QuantusGlobal_]

In Canada, the HTA agency reran 178 company models. Median cost per QALY: C$138,658 in the company's and C$380,251 in the agency's.

It then asked for a lower price in 95% of cases.

Study in the reply.

#MarketAccess #HEOR #HTA #HealthEconomics #QALY

[QuantusAI Global @QuantusGlobal_]

November: https://t.co/OOiAXWJIgQ
January: https://t.co/4wH2NwSR09

[QuantusAI Global @QuantusGlobal_]

The US negotiated the price of 15 drugs. In November it said it would pay 44% less. In January, on the same 15, it said 36%, with no correction notice.

Neither figure is measured savings, because both are a calculation over a past year.

Releases in the reply.

[QuantusAI Global @QuantusGlobal_]

Before: months in Excel to build an economic model.

Now: same data, same rigor, in seconds.

The question isn't whether it works.

It's how long you can go without it.

🔗 Link in bio

#HEOR #MarketAccess #QuantusAI

[QuantusAI Global @QuantusGlobal_]

Kyte et al., JNCI 2019: https://t.co/szPl1lL2xr

[QuantusAI Global @QuantusGlobal_]

160 cancer trials measured their patients' quality of life. 61 never published the result, not even six years later.

The data exists, because the patients answered. But when the committee asks for it, there is nothing to cite.

The study is in the reply.

[QuantusAI Global @QuantusGlobal_]

278 medicines got in on a promise: deliver the confirmatory study later🚦

104 still haven't.

The system pays anyway: +USD 18B over 4 years in public programs alone👇

If the payer asked for that study tomorrow, what would you bring?

#MarketAccess #RealWorldEvidence #Quantus

[QuantusAI Global @QuantusGlobal_]

Manual data extraction: up to 42% error.

AI: over 99% accuracy.

The data tells a different story.

AI + Expert = fewer errors.

🔗 Link in bio

#HEOR #MarketAccess #QuantusAI

[QuantusAI Global @QuantusGlobal_]

New drug, full study. Everything in order. ✅

The committee asked 8 questions. The report answered 1.

One patient group, no comparator. 👇

If 8 questions arrived from your country tomorrow, how many could you answer?

#MarketAccess #HTA #Quantus

[QuantusAI Global @QuantusGlobal_]

Solid dossier. Solid evidence. And yet the drug didn't get in🚫

It was above a ceiling that hadn't moved in 20 years. Until April

What changed wasn't the science. It was the budget👇

Would your value case hold up if the ceiling moved tomorrow?

#MarketAccess #Quantus

[QuantusAI Global @QuantusGlobal_]

If the payer doesn't understand your product's value, that value doesn't exist for the system.

No matter how solid your evidence is.

👉 Swipe to learn more

#ValueStory #MarketAccess #Quantus

[QuantusAI Global @QuantusGlobal_]

New drug approved. Everything in order. ✅

But no one can prove it's better than what already exists.

In Germany: more than half of new drugs compared against placebo, not standard of care. 👇

What are you going to compare against?

#MarketAccess #HealthValue #Quantus

[QuantusAI Global @QuantusGlobal_]

The drug worked. And yet it failed. 💊

Nearly half of launches fail for the same reason: no one understood who signs off on the budget.

(Deloitte, 10 years of launches) 👇

What are you doing to change this story?

#MarketAccess #HealthValue #Quantus

[QuantusAI Global @QuantusGlobal_]

How many of those 67 months of waiting in Latin America are we willing to keep accepting?

The technology to shorten them already exists.

🔗 Link in bio

#MedicineAccess #Pharma #Quantus

[QuantusAI Global @QuantusGlobal_]

5 years, 8 months. The wait in LATAM went up, not down. ⏳

And most of it isn't set by the regulator.

It's demonstrating value, negotiating price, getting paid. 👇

That part is ours to manage.

#MarketAccess #LatinAmerica #AI

[QuantusAI Global @QuantusGlobal_]

$1.36M for one dose. Brazil only pays in full if the child improves. 💉

3 milestones, 4 years, patient-by-patient measurement.

(Brazil's Ministry of Health + Novartis) 👇

Can your evidence stand up to outcomes-based payment?

#OutcomesBasedContracts #MEAs #Quantus

[QuantusAI Global @QuantusGlobal_]

Is your economic model arriving after the payer has already decided?

In market access, arriving late means arriving too late.

Teams that arrive prepared negotiate.
Teams that arrive late, wait.

👉 Swipe

#MarketAccess #Pharma #Quantus